SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Zeev's Turnips - No Politics
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: seminole who wrote (34577)2/28/2002 2:45:35 AM
From: Jdaasoc  Read Replies (2) of 99280
 
The clue is finding drugs with active transport into cancer cells

I thought about that for a minute. Erbitux targets it binding, without any anti-tumor action, to cells that have EGF receptors.
I would think that any biologic agent that binds to cells should change membrane permability/stability to some degree if you want to see it have a promoting effect when administrated with a traditional anti-cancer drug.
Do you know of any side effects of administrating Erbitux. I would expect some reaction such as redness, edema, hives if it was going to work. I am sure IMCL has been wowing potential investors with pictures of fluorescent stained skin cell treated with Erbitux.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News